165 related articles for article (PubMed ID: 33928707)
1. Heat-killed Helicobacter pylori upregulates NKG2D ligands expression on gastric adenocarcinoma cells via Toll-like receptor 4.
Hernández C; Toledo-Stuardo K; García-González P; Garrido-Tapia M; Kramm K; Rodríguez-Siza JA; Hermoso M; Ribeiro CH; Molina MC
Helicobacter; 2021 Aug; 26(4):e12812. PubMed ID: 33928707
[TBL] [Abstract][Full Text] [Related]
2. Immune evasion by proteolytic shedding of natural killer group 2, member D ligands in
Anthofer M; Windisch M; Haller R; Ehmann S; Wrighton S; Miller M; Schernthanner L; Kufferath I; Schauer S; Jelušić B; Kienesberger S; Zechner EL; Posselt G; Vales-Gomez M; Reyburn HT; Gorkiewicz G
Front Immunol; 2024; 15():1282680. PubMed ID: 38318189
[TBL] [Abstract][Full Text] [Related]
3. Helicobacter pylori enhances HLA-C expression in the human gastric adenocarcinoma cells AGS and can protect them from the cytotoxicity of natural killer cells.
Apoorva E; Jacob R; Rao DN; Kumar S
Helicobacter; 2024; 29(2):e13069. PubMed ID: 38516860
[TBL] [Abstract][Full Text] [Related]
4. Helicobacter pylori augments growth of gastric cancers via the lipopolysaccharide-toll-like receptor 4 pathway whereas its lipopolysaccharide attenuates antitumor activities of human mononuclear cells.
Chochi K; Ichikura T; Kinoshita M; Majima T; Shinomiya N; Tsujimoto H; Kawabata T; Sugasawa H; Ono S; Seki S; Mochizuki H
Clin Cancer Res; 2008 May; 14(10):2909-17. PubMed ID: 18483357
[TBL] [Abstract][Full Text] [Related]
5. Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response.
Raynaud A; Desrumeaux K; Vidard L; Termine E; Baty D; Chames P; Vigne E; Kerfelec B
Oncoimmunology; 2020 Dec; 10(1):1854529. PubMed ID: 33457075
[TBL] [Abstract][Full Text] [Related]
6. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
7. Targeting NKG2D/NKG2DL axis in multiple myeloma therapy.
Liu Z; Wang H; Liu H; Ding K; Shen H; Zhao X; Fu R
Cytokine Growth Factor Rev; 2024 Apr; 76():1-11. PubMed ID: 38378397
[TBL] [Abstract][Full Text] [Related]
8. Leveraging NKG2D Ligands in Immuno-Oncology.
Fuertes MB; Domaica CI; Zwirner NW
Front Immunol; 2021; 12():713158. PubMed ID: 34394116
[TBL] [Abstract][Full Text] [Related]
9. Natural killer group 2D receptor and its ligands in cancer immune escape.
Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
[TBL] [Abstract][Full Text] [Related]
10. Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia.
Baragaño Raneros A; Martín-Palanco V; Fernandez AF; Rodriguez RM; Fraga MF; Lopez-Larrea C; Suarez-Alvarez B
Genes Immun; 2015; 16(1):71-82. PubMed ID: 25393931
[TBL] [Abstract][Full Text] [Related]
11. Cutting an NKG2D Ligand Short: Cellular Processing of the Peculiar Human NKG2D Ligand ULBP4.
Zöller T; Wittenbrink M; Hoffmeister M; Steinle A
Front Immunol; 2018; 9():620. PubMed ID: 29651291
[TBL] [Abstract][Full Text] [Related]
12. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
13. The MICA-NKG2D axis in clear cell renal cell carcinoma bolsters MICA as target in immuno-oncology.
Secchiari F; Nuñez SY; Sierra JM; Ziblat A; Regge MV; Raffo Iraolagoitia XL; Rovegno A; Ameri C; Secin FP; Richards N; Ríos Pita H; Vitagliano G; Rico L; Mieggi M; Frascheri F; Bonanno N; Blas L; Trotta A; Friedrich AD; Fuertes MB; Domaica CI; Zwirner NW
Oncoimmunology; 2022; 11(1):2104991. PubMed ID: 35936986
[TBL] [Abstract][Full Text] [Related]
14. The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease.
Stojanovic A; Correia MP; Cerwenka A
Front Immunol; 2018; 9():827. PubMed ID: 29740438
[TBL] [Abstract][Full Text] [Related]
15. NKG2D ligands in glioma stem-like cells: expression in situ and in vitro.
Flüh C; Chitadze G; Adamski V; Hattermann K; Synowitz M; Kabelitz D; Held-Feindt J
Histochem Cell Biol; 2018 Mar; 149(3):219-233. PubMed ID: 29356965
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor (TLR) 2 induced through TLR4 signaling initiated by Helicobacter pylori cooperatively amplifies iNOS induction in gastric epithelial cells.
Uno K; Kato K; Atsumi T; Suzuki T; Yoshitake J; Morita H; Ohara S; Kotake Y; Shimosegawa T; Yoshimura T
Am J Physiol Gastrointest Liver Physiol; 2007 Nov; 293(5):G1004-12. PubMed ID: 17855767
[TBL] [Abstract][Full Text] [Related]
17. Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-kappa B activation and chemokine expression by epithelial cells.
Smith MF; Mitchell A; Li G; Ding S; Fitzmaurice AM; Ryan K; Crowe S; Goldberg JB
J Biol Chem; 2003 Aug; 278(35):32552-60. PubMed ID: 12807870
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D/NKG2DL activation pathway.
Wu HY; Li KX; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Huang YX
Int Immunopharmacol; 2022 Mar; 104():108497. PubMed ID: 34999394
[TBL] [Abstract][Full Text] [Related]
19. Propionibacterium acnes overabundance and natural killer group 2 member D system activation in corpus-dominant lymphocytic gastritis.
Montalban-Arques A; Wurm P; Trajanoski S; Schauer S; Kienesberger S; Halwachs B; Högenauer C; Langner C; Gorkiewicz G
J Pathol; 2016 Dec; 240(4):425-436. PubMed ID: 27538697
[TBL] [Abstract][Full Text] [Related]
20. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
